Mohammed Elmowafy

Dr. Mohammed Elmowafy

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2021 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
MEMohammed Elmowafy
Mohammed Elmowafy
MAMohammad M. Al-Sanea
Mohammad M. Al-Sanea
NLCs have provoked the incessant impulsion for the development of safe and valuable drug delivery systems owing to their exceptional physicochemical and then biocompatible characteristics. Throughout the earlier period, a lot of studies recounting NLCs based formulations have been noticeably increased. They are binary system which contains both solid and liquid lipids aiming to produce less ordered lipidic core. Their constituents particularly influence the physicochemical properties and effectiveness of the final product. NLCs can be fabricated by different techniques which are classified according to consumed energy. More utilization NLCs is essential due to overcome barriers surrounded by the technological procedure of lipid-based nanocarriers’ formulation and increased information of the core mechanisms of their transport via various routes of administration. They can be used in different applications and by different routes such as oral, cutaneous, ocular and pulmonary. This review article seeks to present an overview on the existing situation of the art of NLCs for future clinics through exposition of their applications which shall foster their lucid use. The reported records evidently demonstrate the promise of NLCs for innovate therapeutic applications in the future.

23 February 2023 in Polymers
Verified
Journal Article
Open access
PDF file
MEMohammed Elmowafy
Mohammed Elmowafy
KSKhaled Shalaby
Khaled Shalaby
MEMohammed Elkomy
Mohammed Elkomy
OAOmar Awad Alsaidan
Omar Awad Alsaidan
HGHesham Gomaa
Hesham Gomaa
EMEhab Mohamed Moustafa
Ehab Mohamed Moustafa
In the last few decades, several natural bioactive agents have been widely utilized in the treatment and prevention of many diseases owing to their unique and versatile therapeutic effects, including antioxidant, anti-inflammatory, anticancer, and neuroprotective action. However, their poor aqueous solubility, poor bioavailability, low GIT stability, extensive metabolism as well as short duration of action are the most shortfalls hampering their biomedical/pharmaceutical applications. Different drug delivery platforms have developed in this regard, and a captivating tool of this has been the fabrication of nanocarriers. In particular, polymeric nanoparticles were reported to offer proficient delivery of various natural bioactive agents with good entrapment potential and stability, an efficiently controlled release, improved bioavailability, and fascinating therapeutic efficacy. In addition, surface decoration and polymer functionalization have opened the door to improving the characteristics of polymeric nanoparticles and alleviating the reported toxicity. Herein, a review of the state of knowledge on polymeric nanoparticles loaded with natural bioactive agents is presented. The review focuses on frequently used polymeric materials and their corresponding methods of fabrication, the needs of such systems for natural bioactive agents, polymeric nanoparticles loaded with natural bioactive agents in the literature, and the potential role of polymer functionalization, hybrid systems, and stimuli-responsive systems in overcoming most of the system drawbacks. This exploration may offer a thorough idea of viewing the polymeric nanoparticles as a potential candidate for the delivery of natural bioactive agents as well as the challenges and the combating tools used to overcome any hurdles.

21 May 2014 in Scientific Reports
Verified
Journal Article
Open access
AMAniket Magarkar
Aniket Magarkar
VDVivek Dhawan
Vivek Dhawan
PKParaskevi Kallinteri
Paraskevi Kallinteri
Tapani ViitalaTapani Viitala
Tapani Viitala
MEMohammed Elmowafy
Mohammed Elmowafy
ABAlex Bunker
Alex Bunker
Cholesterol is an important component of all biological membranes as well as drug delivery liposomes. We show here that increasing the level of cholesterol in a phospholipid membrane decreases surface charge in the physiological environment. Through molecular dynamics simulation we have shown that increasing the level of cholesterol decreases Na+ ion binding. Complementary experimental ζ – potential measurements have shown a decreased ζ – potential with increasing cholesterol content, indicative of reduced surface charge. Both experiments and simulations have been carried out on both saturated 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and monounsaturated 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) membranes. This result is particularly important because membrane surface charge plays an important role in the interactions of biomembranes with peripheral membrane proteins and drug delivery liposomes with the immune system.

1 January 2017 in Drug Delivery
Verified
Journal Article
Open access
MEMohammed Elmowafy
Mohammed Elmowafy
HIHany M. Ibrahim
Hany M. Ibrahim
MAMohammed A. Ahmed
Mohammed A. Ahmed
KSKhaled Shalaby
Khaled Shalaby
ASAyman Salama
Ayman Salama
HHHossam Hefesha
Hossam Hefesha
Atorvastatin (AT) is a widely used lipid-regulating drug to reduce cholesterol and triglycerides. Its poor aqueous solubility and hepatic metabolism require development of drug delivery systems able to improve its solubility and bypass hepatic effect. For this purpose, atorvastatin nanostructured lipid carriers (AT-NLCs) were prepared and characterized. AT-NLCs were prepared by emulsification using high-speed homogenization followed by ultrasonication. The prepared NLCs showed particle size between 162.5 ± 12 and 865.55 ± 28 nm while zeta potential values varied between −34 ± 0.29 and −23 ± 0.36 mV. They also showed high encapsulation efficiency (>87%) and amorphous state of the drug in lipid matrix. Pharmacokinetic parameters of optimized formulation (NLC-1; composed of 2% Gelucire® 43/01, 8% Capryol® PGMC, 2% Pluronic®F68 and 0.5% lecithin) revealed 3.6- and 2.1-fold increase in bioavailability as compared to atorvastatin suspension and commercial product (Lipitor®), respectively. Administration of NLC-1 led to significant reduction (p < .05) in the rats’ serum levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and significant increase in high-density lipoprotein (HDL). This improvement was confirmed histologically by minimizing the associated hepatic steatosis. These investigations demonstrated the superiority of NLCs for improvement of oral bioavailability and in vivo performance of AT.

25 August 2015 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
MEMohammed Elmowafy
Mohammed Elmowafy
ASAhmed Samy
Ahmed Samy
MRMohamed A. Raslan
Mohamed A. Raslan
ASAyman Salama
Ayman Salama
RSRagab A. Said
Ragab A. Said
Tapani ViitalaTapani Viitala
Tapani Viitala

1 October 2013 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MEMohammed Elmowafy
Mohammed Elmowafy
Tapani ViitalaTapani Viitala
Tapani Viitala
HIHany M. Ibrahim
Hany M. Ibrahim
SASherif K. Abu-Elyazid
Sherif K. Abu-Elyazid
ASAhmed Samy
Ahmed Samy
MYMarjo Yliperttula
Marjo Yliperttula